![Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA - Parent Project Muscular Dystrophy Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA - Parent Project Muscular Dystrophy](https://www.parentprojectmd.org/wp-content/uploads/2019/01/blog_capricor.png)
Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA - Parent Project Muscular Dystrophy
Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy.… | Instagram
![Fuel Pair of Replacement Screws Wheels Center Cap Cap 1002-53-B, 1002-53: Amazon.com: Industrial & Scientific Fuel Pair of Replacement Screws Wheels Center Cap Cap 1002-53-B, 1002-53: Amazon.com: Industrial & Scientific](https://m.media-amazon.com/images/I/71ewHvq05NL._AC_UF1000,1000_QL80_.jpg)
Fuel Pair of Replacement Screws Wheels Center Cap Cap 1002-53-B, 1002-53: Amazon.com: Industrial & Scientific
![Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet](https://www.thelancet.com/cms/attachment/a94a0d96-3434-4a33-8926-adff3b15c63f/gr2_lrg.gif)
Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet
Long Term Safety and Efficacy of CAP-1002 in late-stage patients with DMD: A New Treatment Approach to Target Skeletal and Cardi
![NS Pharma Shares Community Letter Announcing Partnership With Capricor and Distribution of CAP-1002 - Jett Foundation NS Pharma Shares Community Letter Announcing Partnership With Capricor and Distribution of CAP-1002 - Jett Foundation](https://www.jettfoundation.org/cdn-cgi/image/width=750,height=327,fit=crop,quality=70,gravity=auto,sharpen=1,metadata=none,format=auto,onerror=redirect/wp-content/uploads/2022/03/NSPharmaandCapricor-01.png)
NS Pharma Shares Community Letter Announcing Partnership With Capricor and Distribution of CAP-1002 - Jett Foundation
![The Lancet Publishes Positive Results from Capricor's Phase 2 Study of CAP- 1002 in Late-Stage Duchenne - Parent Project Muscular Dystrophy The Lancet Publishes Positive Results from Capricor's Phase 2 Study of CAP- 1002 in Late-Stage Duchenne - Parent Project Muscular Dystrophy](https://www.parentprojectmd.org/wp-content/uploads/2021/09/capricor-blog.png)